Tagged with Switzerland

Switzerland The first company to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, Madrigal Pharmaceuticals is redefining how the world tackles fatty liver disease. From its new European base in Zug, the firm is building an entirely new therapeutic category while spearheading one of the most ambitious global launches…

Switzerland As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. With the United States imposing tariffs of up to 39 percent on Swiss goods and threatening further measures, the pressure on Switzerland’s most important industrial sector – responsible for ten percent of GDP and over…

Switzerland Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability to offer diverse, high-impact career paths within a single global organisation. She discusses the company’s leadership in diabetes and cardiac…

Switzerland With over seven decades of innovation behind it, Lupin has evolved from an Indian pioneer in anti-tuberculosis therapies into a global pharmaceutical leader shaping the future of complex generics, speciality care, and biosimilars. As the company accelerates its European expansion, Laurent Renaudie shares how Lupin’s entrepreneurial culture, patient-centred mission, and…

Switzerland Clinigen is in the midst of a major transformation, repositioning itself as a pure services partner focused on bridging patient access to critical medicines worldwide. Its recent acquisition of SSI Strategy underscores this shift, combining SSI’s strategic depth, established U.S. and European footprint, and innovative partnership models with Clinigen’s global…

Switzerland SpiroChem has evolved from a niche ETH Zurich spin-out into a global discovery partner recognised for tackling some of the most complex challenges in modern drug design. Over more than a decade, co-founder and CEO Thomas Fessard has steered the company’s transformation from a product-focused catalogue into a solution-driven, modality-agnostic…

Switzerland Giancarlo Benelli, SVP, Head of Europe at BeOne Medicines (BeOne), draws on nearly three decades of pharmaceutical leadership to drive the company’s rapid growth in oncology and haematology in Europe, with flagship assets like zanubrutinib and tislelizumab. Over the last few years, BeOne has greatly expanded its clinical trials in…

Switzerland Marc Gitzinger, CEO and Founder of BioVersys, launched the company from his doctoral research at ETH Zurich on antibiotic resistance. Bioversys began with a tuberculosis programme; today, it owns two proprietary platforms to develop new antibiotics and leads with BV-100, advancing to Phase III for severe hospital infections. Gitzinger also…

Switzerland Chantal Friebertshäuser, SVP Europe & Middle East, is spearheading Moderna’s ambitious expansion beyond COVID-19 vaccines, leveraging mRNA technology to target cancers and latent viruses across diverse markets. She champions a hyper-localised strategy to navigate Europe and the Middle East’s complex healthcare landscapes. Her vision positions Moderna not as a pandemic…

Switzerland Neil Archer, Executive Vice President International at Madrigal, discusses the company’s pioneering role in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a progressive liver disease with no prior approved therapies. He shares insights on Madrigal’s breakthrough first-in-class treatment, the challenges of launching an entirely new therapeutic category, and the bold international expansion…

Switzerland QIAGEN’s Sample Technologies portfolio sits at the core of the company’s mission to deliver the highest-quality products to enable valuable molecular insights to more than 500,000 customers across life sciences and clinical diagnostics. Under the leadership of Michael Scheffler, Vice President and Head of Global Sample Technologies, this portfolio continues…

Switzerland Kasha Witkos, Senior Vice President and Head of International Business at Alnylam Pharmaceuticals, shares her journey from academic researcher to global biotech leader, driven by personal family experience of chronic disease.  Witkos highlights Alnylam’s pioneering role in delivering RNA interference (RNAi) technology to patients around the world, the company’s global…